PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	15-18	beta-site APP cleaving enzyme 1	Mus musculus	136-152	
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	15-18	beta-site APP cleaving enzyme 1	Mus musculus	154-160	
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	26-29	beta-site APP cleaving enzyme 1	Mus musculus	136-152	
24759994-3	2014	Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Abeta), and promoted increased beta-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints.	efavirenz	26-29	beta-site APP cleaving enzyme 1	Mus musculus	154-160	
24759994-6	2014	EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Abeta generation while 3TC, AZT, or vehicle control did not.	efavirenz	0-3	beta-site APP cleaving enzyme 1	Mus musculus	62-68	
24759994-6	2014	EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Abeta generation while 3TC, AZT, or vehicle control did not.	efavirenz	11-14	beta-site APP cleaving enzyme 1	Mus musculus	62-68